IASLC 2026 World Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

Efficacy and Safety of GFH375 in Advanced Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Ziming Li, MD, PhD

Department of Medical Oncology, Shanghai Chest Hospital,
Shanghai Jiao Tong University School of Medicine--Shanghai, China

, Ziming Li, Xinghao Ai, Peng Chen, Wenxiu Yao, Hong Zong, Lin Wu, Tongmei Zhang, Jianbo He, Qitao Yu, Zuoxing Niu, Yuping Sun, Jian Fang, Jianxin Xue, Anna Li, Kejing Tang, Lingjun Zhu, Zhengbo Song, Ying Yuan, Meili Sun, Lin Zhao, Yingying Du, Yu Wang, Haige Shen, Huaqiang Zhu, Chanli Zheng, Shuang Wang, Zhao Cui

NSCLC at 600 mg (n=75)



NSCLC at 600 mg (n=71)*


600mg QD (N=75)
Event, n(%)
40 (53.3)
Censor, n(%)
35 (46.7)
PFS probability
0.75
0.50
0.25
0.00
Follow-up time (months)
Number at risk



Adverse events, n(%)	600 mg QD (N=75)

Adverse events, n(%)	ICIs 28~90 days* (n=48)	ICIs >90 days (n=27)


KRAS status
Undetectable
Detectable
N
Median PFS (95% CI), months
KRASG12D
KRASG12D
1.00
0.75
0.50
0.25
0.00
Undetectable
Detectable
Altered
Follow up time (months)

52.1% confirmed ORR

8.3 months of median PFS

9.6 months among taxane-naïve patients

Median OS not reached

Thank You